Dr. Usman's Cardiology Notes

Management of Calcified Coronary Lesions: A Practical Guide for Interventional Cardiologists Coronary artery calcification (CAC) is one of the most challenging scenarios encountered during percutaneous coronary intervention (PCI). Calcified plaques reduce vessel compliance, make lesion crossing difficult, impair stent expansion, and increase the risk of procedural complications. As the population ages and diabetes and chronic kidney disease become more prevalent, interventional cardiologists are encountering heavily calcified lesions with increasing frequency. Modern PCI success depends not only on opening the artery but also on achieving optimal lesion preparation before stent implantation. Inadequately treated calcium remains one of the strongest predictors of stent failure. --- Why Calcified Lesions Matter Calcified plaques are associated with: Difficult guidewire and device delivery Balloon-resistant lesions Poor stent expansion Stent malapposition Edge dissection Stent thrombosis ...

  Selatogrel: A Potential Game-Changer in the Early Treatment of Acute Coronary Syndrome (ACS) Acute coronary syndrome (ACS) remains one of the leading causes of death and disability worldwide. In patients with myocardial infarction, every minute of delayed treatment increases the amount of irreversible myocardial damage. While rapid reperfusion with primary PCI remains the cornerstone of management, early and effective platelet inhibition is equally critical to prevent thrombus propagation and recurrent ischemic events. Current oral P2Y12 inhibitors such as clopidogrel, prasugrel, and ticagrelor are effective but have important limitations. Their onset may be delayed by impaired gastrointestinal absorption, especially in patients with STEMI, cardiogenic shock, opioid use, or persistent vomiting. This has driven the search for a rapidly acting, easily administered antiplatelet agent that can be given before hospital arrival. Selatogrel is one of the most promising investigational d...

  Postural Orthostatic Tachycardia Syndrome (POTS): A Detailed Guide to Management Feeling dizzy every time you stand up is not just "low blood pressure" for everyone. For many people, it is a sign of Postural Orthostatic Tachycardia Syndrome (POTS), a chronic disorder of the autonomic nervous system that can significantly affect daily life. Patients often struggle with fatigue, brain fog, palpitations, exercise intolerance, and even fainting. Although there is no universal cure, appropriate treatment allows many individuals to regain function and improve their quality of life. This article reviews the current approach to POTS management based on recent expert consensus and evidence. --- What is POTS? Postural Orthostatic Tachycardia Syndrome (POTS) is a disorder characterized by excessive heart rate increase on standing without significant orthostatic hypotension. Diagnostic Criteria Adults: Increase in heart rate ≥30 beats/min within 10 minutes of standing or head-up tilt N...

  Mavacamten: Indications, Monitoring, and Practical Clinical Use in Obstructive Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, affecting approximately 1 in 500 people. While many patients remain asymptomatic, others develop significant symptoms due to obstruction of the left ventricular outflow tract (LVOT). Until recently, treatment options mainly focused on reducing symptoms with medications or relieving obstruction through invasive septal reduction procedures. The introduction of mavacamten has changed the management of symptomatic obstructive HCM. Rather than simply controlling heart rate or contractility, mavacamten directly targets the underlying disease mechanism, making it the first disease-specific medical therapy approved for obstructive HCM. This article reviews its mechanism of action, indications, patient selection, monitoring requirements, and practical clinical considerations. --- What is Mavacamte...

Stokes-Adams Attack: Causes, Symptoms, Diagnosis, and Management Introduction A Stokes-Adams attack (also called Adams-Stokes attack) is a sudden, transient episode of loss of consciousness (cardiac syncope) caused by a temporary but profound reduction in cerebral blood flow due to a severe cardiac rhythm disturbance. Classically, it results from complete atrioventricular (AV) block with prolonged ventricular asystole, although several other bradyarrhythmias and tachyarrhythmias may produce the same clinical syndrome.  It is a medical emergency because it may be the first manifestation of a life-threatening arrhythmia and carries a significant risk of sudden cardiac death if untreated. --- Historical Background The syndrome is named after Irish physicians: William Stokes (1804–1878) Robert Adams (1791–1875) They described patients with recurrent syncope associated with profound bradycardia long before electrocardiography was available.  --- Definition A Stokes-Adams attack is:...

📌 Tissue Doppler Imaging (TDI): Understanding S′, e′, a′ and the Tei Index Tissue Doppler Imaging (TDI) is a valuable echocardiographic technique used to assess both systolic and diastolic myocardial function through measurement of mitral annular velocities. 🔹 S′ (Systolic Velocity) • Represents longitudinal LV systolic contraction. • Measured during ventricular systole. • Reduced S′ suggests impaired LV systolic function. 🔹 e′ (Early Diastolic Velocity) • Reflects active myocardial relaxation. • A key parameter for assessing LV diastolic function. • Reduced e′ indicates impaired relaxation and diastolic dysfunction. 🔹 a′ (Late Diastolic Velocity) • Generated by atrial contraction. • Becomes more prominent when ventricular relaxation is impaired. 📏 Important Time Intervals ⏱ IVCT (Isovolumic Contraction Time) • Interval between mitral valve closure and aortic valve opening. ⏱ ET (Ejection Time) • Duration of ventricular ejection. ⏱ IVRT (Isovolumic Relaxation Time) • Interval betw...

  Drugs for Triglyceride Lowering: A Practical Clinical Guide --- Introduction Hypertriglyceridemia is a common lipid disorder associated with an increased risk of acute pancreatitis and, in selected populations, atherosclerotic cardiovascular disease (ASCVD). While lifestyle modification remains the cornerstone of therapy, pharmacological treatment is often required in patients with severe hypertriglyceridemia or persistent elevation despite non-pharmacological measures. This article reviews the major drug classes used for triglyceride (TG) reduction and their clinical applications. --- Understanding Triglyceride Levels Triglyceride Level Classification <150 mg/dL Normal 150–199 mg/dL Mild elevation 200–499 mg/dL Moderate elevation ≥500 mg/dL Severe hypertriglyceridemia ≥1000 mg/dL Very severe hypertriglyceridemia The primary therapeutic goal in severe hypertriglyceridemia is prevention of acute pancreatitis. --- 1. Fibrates Agents Fenofibrate Gemfibrozil Mechanism of Action Fi...